Cargando…
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
BACKGROUND: Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict the prog...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990312/ https://www.ncbi.nlm.nih.gov/pubmed/36882764 http://dx.doi.org/10.1186/s12885-023-10700-0 |
_version_ | 1784901913453527040 |
---|---|
author | Kawahara, Takashi Saigusa, Yusuke Yoneyama, Shuko Kato, Masashi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tabata, Kenichi Tsumura, Hideyasu Iwamura, Masatsugu Makiyama, Kazuhide Uemura, Hiroji Miyoshi, Yasuhide |
author_facet | Kawahara, Takashi Saigusa, Yusuke Yoneyama, Shuko Kato, Masashi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tabata, Kenichi Tsumura, Hideyasu Iwamura, Masatsugu Makiyama, Kazuhide Uemura, Hiroji Miyoshi, Yasuhide |
author_sort | Kawahara, Takashi |
collection | PubMed |
description | BACKGROUND: Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict the prognosis of patients with mCRPC who received abiraterone acetate (ABI) and/or enzalutamide (ENZ). METHODS: In total, 568 patients with mCRPC who underwent ABI and/or ENZ between 2012 and 2017 were enrolled. A prognostic nomogram based on the risk factors was developed using the Cox proportional hazards regression model and clinically important factors. The discriminatory ability of the nomogram was assessed according to the concordance index (C-index). A 5-fold cross-validation was repeated 2000 times to estimate the C-index, and the means of the estimated C-index for the training and validation sets were determined. A calculator based on this nomogram was then developed. RESULTS: The median overall survival (OS) was 24.7 months. Multivariate analysis showed that the time to CRPC, pre-chemotherapy, baseline prostate-specific antigen, baseline alkaline phosphatase, and baseline lactate dehydrogenase levels were independent risk factors for OS (hazard ratio [HR]: 0.521, 1.681, 1.439, 1.827, and 12.123, p = 0.001, 0.001, < 0.001, 0.019, and < 0.001, respectively). The C-index was 0.72 in the training cohort and 0.71 in the validation cohort. CONCLUSIONS: We developed a nomogram and calculator to predict OS in Japanese patients with mCRPC who received ABI and/or ENZ. Reproducible prognostic prediction calculators for mCRPC will facilitate greater accessibility for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10700-0. |
format | Online Article Text |
id | pubmed-9990312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99903122023-03-08 Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide Kawahara, Takashi Saigusa, Yusuke Yoneyama, Shuko Kato, Masashi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tabata, Kenichi Tsumura, Hideyasu Iwamura, Masatsugu Makiyama, Kazuhide Uemura, Hiroji Miyoshi, Yasuhide BMC Cancer Research BACKGROUND: Despite the widespread availability of medication choices for metastatic castration-resistant prostate cancer (mCRPC), biomarkers to predict the efficacy of each mCRPC treatment have not yet been established. This study developed a prognostic nomogram and a calculator to predict the prognosis of patients with mCRPC who received abiraterone acetate (ABI) and/or enzalutamide (ENZ). METHODS: In total, 568 patients with mCRPC who underwent ABI and/or ENZ between 2012 and 2017 were enrolled. A prognostic nomogram based on the risk factors was developed using the Cox proportional hazards regression model and clinically important factors. The discriminatory ability of the nomogram was assessed according to the concordance index (C-index). A 5-fold cross-validation was repeated 2000 times to estimate the C-index, and the means of the estimated C-index for the training and validation sets were determined. A calculator based on this nomogram was then developed. RESULTS: The median overall survival (OS) was 24.7 months. Multivariate analysis showed that the time to CRPC, pre-chemotherapy, baseline prostate-specific antigen, baseline alkaline phosphatase, and baseline lactate dehydrogenase levels were independent risk factors for OS (hazard ratio [HR]: 0.521, 1.681, 1.439, 1.827, and 12.123, p = 0.001, 0.001, < 0.001, 0.019, and < 0.001, respectively). The C-index was 0.72 in the training cohort and 0.71 in the validation cohort. CONCLUSIONS: We developed a nomogram and calculator to predict OS in Japanese patients with mCRPC who received ABI and/or ENZ. Reproducible prognostic prediction calculators for mCRPC will facilitate greater accessibility for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10700-0. BioMed Central 2023-03-07 /pmc/articles/PMC9990312/ /pubmed/36882764 http://dx.doi.org/10.1186/s12885-023-10700-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kawahara, Takashi Saigusa, Yusuke Yoneyama, Shuko Kato, Masashi Kojima, Ippei Yamada, Hiroshi Kamihira, Osamu Tabata, Kenichi Tsumura, Hideyasu Iwamura, Masatsugu Makiyama, Kazuhide Uemura, Hiroji Miyoshi, Yasuhide Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title | Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title_full | Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title_fullStr | Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title_full_unstemmed | Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title_short | Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
title_sort | development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990312/ https://www.ncbi.nlm.nih.gov/pubmed/36882764 http://dx.doi.org/10.1186/s12885-023-10700-0 |
work_keys_str_mv | AT kawaharatakashi developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT saigusayusuke developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT yoneyamashuko developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT katomasashi developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT kojimaippei developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT yamadahiroshi developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT kamihiraosamu developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT tabatakenichi developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT tsumurahideyasu developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT iwamuramasatsugu developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT makiyamakazuhide developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT uemurahiroji developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide AT miyoshiyasuhide developmentandvalidationofasurvivalnomogramandcalculatorformalepatientswithmetastaticcastrationresistantprostatecancertreatedwithabirateroneacetateandorenzalutamide |